JP2016526021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526021A5 JP2016526021A5 JP2016513057A JP2016513057A JP2016526021A5 JP 2016526021 A5 JP2016526021 A5 JP 2016526021A5 JP 2016513057 A JP2016513057 A JP 2016513057A JP 2016513057 A JP2016513057 A JP 2016513057A JP 2016526021 A5 JP2016526021 A5 JP 2016526021A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- target polypeptide
- corrole
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- LYNARWYQOUZXDY-UHFFFAOYSA-N corrole Chemical compound N1C(C=C2NC(=CC=3NC4=CC=3)C=C2)=CC=C1C=C1C=CC4=N1 LYNARWYQOUZXDY-UHFFFAOYSA-N 0.000 claims 5
- 238000003384 imaging method Methods 0.000 claims 4
- 239000011572 manganese Substances 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-Bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Claims (23)
- 標的ポリペプチドとコロールとを含む標的ナノ粒子を含む組成物であって、前記コロールはマンガン（Ｍｎ）または鉄（Ｆｅ）を含む、組成物。
- 前記標的ポリペプチドは腫瘍標的ポリペプチドである、請求項１に記載の組成物。
- 癌の治療に使用するための請求項２に記載の組成物。
- 癌を治療するための医薬の製造に使用するための請求項２に記載の組成物。
- 対象における状態を画像化するのに使用するための請求項１または２に記載の組成物。
- 対象における状態を画像化するための診断剤の製造に使用するための請求項１または２に記載の組成物。
- 前記状態は癌である、請求項５または６に記載の組成物。
- 前記画像化は磁気共鳴画像法（ＭＲＩ）による、請求項５〜７のいずれか一項に記載の組成物。
- 対象における癌の治療に使用するため、および対象における癌を画像化するのに使用するための請求項１または２に記載の組成物。
- 前記コロールはスルホン化される、請求項１〜９のいずれか一項に記載の組成物。
- 前記コロールはマンガン（Ｍｎ）を含む、請求項１〜１０のいずれか一項に記載の組成物。
- 前記コロールはＳ２Ｍｎである、請求項１〜１１のいずれか一項に記載の組成物。
- 前記コロールは鉄（Ｆｅ）を含む、請求項１〜１０のいずれか一項に記載の組成物。
- 前記標的ポリペプチドはＨｅｒ部分を含む、請求項１〜１３のいずれか一項に記載の組成物。
- 前記標的ポリペプチドは細胞透過タンパク質を含む、請求項１〜１４のいずれか一項に記載の組成物。
- 前記標的ポリペプチドはペントンベースの部分を含む、請求項１〜１５のいずれか一項に記載の組成物。
- 前記標的ポリペプチドはＨｅｒＰＢＫ１０分子である、請求項１〜１６のいずれか一項に記載の組成物。
- 前記ナノ粒子はＨｅｒＭｎである、請求項１〜９のいずれか一項に記載の組成物。
- 前記ナノ粒子はＨｅｒＦｅである、請求項１〜９のいずれか一項に記載の組成物。
- 前記標的ポリペプチドはＨＥＲ２＋腫瘍細胞を標的とする、請求項１〜１９のいずれか一項に記載の組成物。
- 前記組成物は、エアロゾル、経鼻、経口、経粘膜、経皮、静脈内または非経口投与用に製剤化される、請求項１〜２０のいずれか一項に記載の組成物。
- 前記医薬組成物は非経口投与用に製剤化される、請求項１〜２１のいずれか一項に記載の組成物。
- 前記医薬組成物は静脈投与用に製剤化される、請求項１〜２１のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361821106P | 2013-05-08 | 2013-05-08 | |
| US61/821,106 | 2013-05-08 | ||
| PCT/US2014/037234 WO2014182868A1 (en) | 2013-05-08 | 2014-05-08 | Targeting corroles for tumor toxicity and mri |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526021A JP2016526021A (ja) | 2016-09-01 |
| JP2016526021A5 true JP2016526021A5 (ja) | 2017-06-22 |
| JP6640715B2 JP6640715B2 (ja) | 2020-02-05 |
Family
ID=51864925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513057A Expired - Fee Related JP6640715B2 (ja) | 2013-05-08 | 2014-05-08 | 腫瘍毒性に対する標的コロールおよびｍｒｉ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9757386B2 (ja) |
| EP (2) | EP2993983B1 (ja) |
| JP (1) | JP6640715B2 (ja) |
| KR (1) | KR20160008523A (ja) |
| CN (2) | CN108451930A (ja) |
| AU (2) | AU2014262653B2 (ja) |
| CA (1) | CA2910030A1 (ja) |
| DK (1) | DK2993983T3 (ja) |
| ES (1) | ES2791043T3 (ja) |
| HK (1) | HK1221870A1 (ja) |
| IL (1) | IL265935B (ja) |
| MX (1) | MX2015015434A (ja) |
| PL (1) | PL2993983T3 (ja) |
| PT (1) | PT2993983T (ja) |
| RU (1) | RU2674146C2 (ja) |
| WO (1) | WO2014182868A1 (ja) |
| ZA (1) | ZA201508092B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| JP6618360B2 (ja) | 2012-08-03 | 2019-12-11 | セダーズ−シナイ メディカル センター | 薬物送達タンパク質の輸送向上変異体の単離 |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| AU2015206271B2 (en) | 2014-01-17 | 2020-02-27 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| AU2015240460A1 (en) | 2014-04-04 | 2016-09-15 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle |
| US20200345846A1 (en) * | 2017-08-31 | 2020-11-05 | Technion Research & Development Foundation Limited | Corrole compositions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA129822A (en) | 1910-08-24 | 1910-12-13 | The John Bertram And Sons Company, Limited | Motor controlling apparatus |
| CA140995A (en) | 1912-03-05 | 1912-06-11 | Davydd C. Hughes | Type plate mechanism |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| WO2002094318A1 (en) | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
| IL159534A0 (en) * | 2001-07-02 | 2004-06-01 | Technion Res & Dev Foundation | Method for the preparation of selectively-substituted corroles and new substituted corroles |
| US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| US8791099B2 (en) * | 2007-08-28 | 2014-07-29 | Technion Research And Development Foundation Ltd. | Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
| US20110098262A1 (en) * | 2008-01-31 | 2011-04-28 | Yondim Moussa B H | Corroles for neuroprotection and neurorescue |
| US8541568B2 (en) | 2008-05-24 | 2013-09-24 | Hai Yan | Compositions and methods using siRNA molecules for treatment of gliomas |
| US9012622B2 (en) | 2008-12-31 | 2015-04-21 | Patrick Y. Lu | Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| CN101704820A (zh) * | 2009-09-24 | 2010-05-12 | 江苏大学 | 三(4-氯苯基)咔咯化合物及其合成方法 |
| US20130065778A1 (en) | 2010-01-26 | 2013-03-14 | Yale University | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy |
| US9642860B2 (en) * | 2011-08-15 | 2017-05-09 | Technion Research & Development Foundation Limited | Combinations of corroles and statins |
| JP6618360B2 (ja) | 2012-08-03 | 2019-12-11 | セダーズ−シナイ メディカル センター | 薬物送達タンパク質の輸送向上変異体の単離 |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| AU2015206271B2 (en) | 2014-01-17 | 2020-02-27 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| AU2015240460A1 (en) | 2014-04-04 | 2016-09-15 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle |
| MX2018014576A (es) | 2016-05-27 | 2019-06-06 | Cedars Sinai Medical Center | Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. |
-
2014
- 2014-05-08 US US14/272,610 patent/US9757386B2/en active Active
- 2014-05-08 CA CA2910030A patent/CA2910030A1/en not_active Abandoned
- 2014-05-08 CN CN201810246983.5A patent/CN108451930A/zh not_active Withdrawn
- 2014-05-08 EP EP14794410.2A patent/EP2993983B1/en active Active
- 2014-05-08 CN CN201480025009.6A patent/CN105307499B/zh not_active Expired - Fee Related
- 2014-05-08 EP EP20157304.5A patent/EP3730155A1/en not_active Withdrawn
- 2014-05-08 RU RU2015152033A patent/RU2674146C2/ru active
- 2014-05-08 JP JP2016513057A patent/JP6640715B2/ja not_active Expired - Fee Related
- 2014-05-08 PT PT147944102T patent/PT2993983T/pt unknown
- 2014-05-08 KR KR1020157030349A patent/KR20160008523A/ko not_active Application Discontinuation
- 2014-05-08 ES ES14794410T patent/ES2791043T3/es active Active
- 2014-05-08 AU AU2014262653A patent/AU2014262653B2/en not_active Ceased
- 2014-05-08 DK DK14794410.2T patent/DK2993983T3/da active
- 2014-05-08 PL PL14794410T patent/PL2993983T3/pl unknown
- 2014-05-08 WO PCT/US2014/037234 patent/WO2014182868A1/en active Application Filing
- 2014-05-08 MX MX2015015434A patent/MX2015015434A/es unknown
-
2015
- 2015-11-02 ZA ZA2015/08092A patent/ZA201508092B/en unknown
-
2016
- 2016-08-25 HK HK16110127.7A patent/HK1221870A1/zh unknown
-
2017
- 2017-06-15 US US15/624,228 patent/US10709801B2/en active Active
-
2018
- 2018-10-17 AU AU2018250401A patent/AU2018250401B2/en not_active Ceased
-
2019
- 2019-04-10 IL IL265935A patent/IL265935B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526021A5 (ja) | ||
| JP2016538344A5 (ja) | ||
| JP2018513104A5 (ja) | ||
| JP2016535009A5 (ja) | ||
| JP2017533920A5 (ja) | ||
| JP2015536964A5 (ja) | ||
| JP2015530404A5 (ja) | ||
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| JP2016528162A5 (ja) | ||
| RU2016114498A (ru) | Способы и композиции для лечения раковых заболеваний | |
| JP2011079858A5 (ja) | ||
| JP2019521180A5 (ja) | ||
| JP2014508804A5 (ja) | ||
| JP2017508724A5 (ja) | ||
| JP2014534269A5 (ja) | ||
| Tan et al. | Sustained release and cytotoxicity evaluation of carbon nanotube‐mediated drug delivery system for betulinic acid | |
| JP2013501791A5 (ja) | ||
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| WO2015154059A3 (en) | Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle | |
| RU2015152033A (ru) | Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт | |
| JP2019506862A5 (ja) | ||
| JP2019517507A5 (ja) | ||
| JP2015514756A5 (ja) | ||
| JP2016527202A5 (ja) | ||
| JP2014506233A5 (ja) |